Altimmune announces new analyses at EASL on MASH Resolution Index

Altimmune (ALT) announced the presentation of new analyses at the European Association for the Study of the Liver, EASL, Congress in Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune’s 1:1 GLP-1/glucagon dual receptor agonist. The composite MASHResInd score is a robust, non-invasive marker for liver histology improvement, with potential application across clinical research and practice. In the analyses presented at EASL, 24 weeks of treatment with pemvidutide resulted in MASHResInd responses in 69.2%, 92.3% and 90.9% of subjects receiving 1.2 mg, 1.8 mg, and 2.4 mg of pemvidutide, respectively, compared with 22.2% in subjects receiving placebo.